Outlook Therapeutics, Inc. (OTLK)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$7.8M
Cash & Equivalents
$22.8M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$251M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-07-29 Pdufa —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05112861 A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment ... PHASE3 Active Not Recruiting 120

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-06-16 8-K Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) - EXHIBIT 99.1 EDGAR
2026-06-01 8-K Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) - EXHIBIT 99.1 EDGAR
2026-05-26 8-K Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) - EXHIBIT 99.1 EDGAR

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for OTLK.

SEC EDGAR Filings

All SEC filings for Outlook Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.